الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 66 |  |  |
| | | from | 66 | | |
Abstract
Chronic conditions, medicines, poor dental hygiene, decreased salivary flow, or immune system damage can all lead to Candida infection in the elderly. In Finland, up to 75% of the elderly carry oral yeast. Although Candida colonization may be asymptomatic, high growth usually results in local candidiasis, which is characterized by numerous forms of mucosal lesions and symptoms. It is consequently critical that yeast proliferation be regulated.
Treatments based on topical or systemic antifungal and disinfectant administration, as well as the integration of slow-release antifungal/antimicrobial drugs into denture-base materials, have also been proposed. Although antifungal medicines have shown useful in treating clinical symptoms of DS, they are not without risks in fact, high rates of early post-treatment relapse and recurrence have been reported, while prolonged therapeutic regimens or multiple cycles of treatment significantly increase the risk of potential systemic adverse effects and the induction of antifungal drug resistance in resident fungal strains, making their use in the treatment of DS challenging. In recent years, the administration of certain probiotic formulations has been examined as a means of comparing oral colonization by Candida spp. in denture wearers in the presence and absence of DS, with varying outcomes.
Probiotic bacteria, such as Lactobacillus, are known to limit the growth of pathogenic germs. They also affect the host’s microbial balance by lowering the proliferation of pathogens like Candida.
This study aimed to assess the preventive effect of using a daily dose of commercial probiotics containing different lactobacilli strains on the oral of Candida spp. colonization in denture wearers. Also, this study aims to evaluate the relapse in oral candida colonization levels after 4 weeks of cessation of probiotics intake.
The current randomized double-blinded controlled clinical trial included 48 new complete denture wearers with detectable levels of Candida but without clinical symptoms. Participants in the probiotics group received a daily dose of probiotics lozenges for eight weeks versus the placebo tablets taken by the participants in the placebo group. Microbiological mouth-rinse samples determined the Candida count and species identification at different time intervals: baseline, two weeks after denture delivery, after 4 and 8 weeks of intervention, and four weeks post-intervention follow-up.
The results showed a significant reduction in the count in the fourth and twelve weeks in all patients who received probiotics while a highly significant difference was observed in the eighth week (p<0.0001). On comparing both groups, a statistically significant difference was noticed in Candida species (p≤0.05) in the eighth week, while there was no statistically significant difference between placebo and probiotics at the twelfth week of post-treatment follow-up.
Within the limitation of this study, it can be concluded that the probiotic lozenges had a potent antimycotic efficiency in asymptomatic new denture wearers, with short-term extended preventive effects after intervention cessation.